The CDMO outfit iBio has netted a deal that sees it gain access to an AI-based platform as well as new therapeutic candidates as it looks to dive further into drug discovery.
BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®,ntoday announced a research collaboration with the University of Texas nSouthwestern Medical Center (“UT Southwestern”) to explore in solid ntumors the anti-cancer potential of the molecule that is part of the nIBIO-100 program.
iBio, Inc., a biotech innovator and biologics contract development and manufacturing organization (CDMO), has entered into its first Statement of Work (SoW) under a Master Services Agreement with Belgium-based ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming System.
Adding to its growing presence in Southern Nevada, The Pennant Group (NASDAQ:PNTG) acquired Harmony Hospice of Las Vegas, Nevada, effective October 1, 2020.